A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation
Open Access
- 11 January 2011
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 13 (1), R3
- https://doi.org/10.1186/bcr2804
Abstract
Estrogen receptor positive breast cancers often have high levels of Mdm2. We investigated if estrogen signaling in such breast cancers occurred through an Mdm2 mediated pathway with subsequent inactivation of p53.Keywords
This publication has 61 references indexed in Scilit:
- The Ability to Generate Senescent Progeny as a Mechanism Underlying Breast Cancer Cell HeterogeneityPLOS ONE, 2010
- Mechanisms of regulatory diversity within the p53 transcriptional networkOncogene, 2008
- p53 in health and diseaseNature Reviews Molecular Cell Biology, 2007
- The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expressionMolecular Oncology, 2007
- Myc stabilization in response to estrogen and phospholipase D in MCF‐7 breast cancer cellsFEBS Letters, 2006
- p53 and breast cancer, an updateEndocrine-Related Cancer, 2006
- A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in HumansCell, 2004
- Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cellsBritish Journal of Cancer, 2004
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992